Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab Dose-Ranging in Active Crohn's Disease
NCT00269854Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 1995
- Primary completion
- Oct 1996
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of infliximab in Crohn's disease (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients achieving a clinical response at 4 weeks. Started Jun 1995; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00269854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269854.